This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Stopping vs. Continuing Aspirin before Coronary Artery Surgery
In this trial 2100 undergoing coronary surgery were randomized to aspirin 100mg or placebo. The primary outcome was defined as a composite of death and thrombotic complications (myocardial infarction, stroke, pulmonary embolism, renal failure or bowel infarction) at 30 days.
There was no difference between the two treatment groups for the primary endpoint (aspirin group 19.3% versus placebo group 20.4% , p=0.55). Other endpoints included cardiac tamponade (aspirin group 1.1% versus placebo 0.4%, p=0.08) and major hemorrhage leading to reoperation (aspirin group 1.8% versus placebo 2.1%, p=0.75).
The authors conclude that preoperative aspirin did not lead to a higher risk of death, thrombotic complications or reoperation due to bleeding.